Ontology highlight
ABSTRACT:
SUBMITTER: Nami B
PROVIDER: S-EPMC6210751 | biostudies-other | 2018 Sep
REPOSITORIES: biostudies-other
Nami Babak B Maadi Hamid H Wang Zhixiang Z
Cancers 20180920 10
Human epidermal growth factor receptor (HER) 2 (HER2) is overexpressed in 20⁻30% of breast cancers. HER2 is a preferred target for treating HER2-positive breast cancer. Trastuzumab and pertuzumab are two HER2-targeted monoclonal antibodies approved by the Food and Drug Administration (FDA) to use as adjuvant therapy in combination with docetaxel to treat metastatic HER2-positive breast cancer. Adding the monoclonal antibodies to treatment regimen has changed the paradigm for treatment of HER2-po ...[more]